GC-MS  ||| S:0 E:6 ||| JJ
lipidomic  ||| S:6 E:16 ||| JJ
profiling  ||| S:16 E:26 ||| NN
of  ||| S:26 E:29 ||| IN
the  ||| S:29 E:33 ||| DT
echinoderm  ||| S:33 E:44 ||| JJ
Marthasterias  ||| S:44 E:58 ||| JJ
glacialis  ||| S:58 E:68 ||| NN
and  ||| S:68 E:72 ||| CC
screening  ||| S:72 E:82 ||| NN
for  ||| S:82 E:86 ||| IN
activity  ||| S:86 E:95 ||| NN
against  ||| S:95 E:103 ||| IN
human  ||| S:103 E:109 ||| JJ
cancer  ||| S:109 E:116 ||| NN
and  ||| S:116 E:120 ||| CC
non-cancer  ||| S:120 E:131 ||| JJ
cell  ||| S:131 E:136 ||| NN
lines  ||| S:136 E:142 ||| NNS
Marine  ||| S:142 E:149 ||| NNP
organisms  ||| S:149 E:159 ||| NNS
have  ||| S:159 E:164 ||| VBP
been  ||| S:164 E:169 ||| VBN
increasingly  ||| S:169 E:182 ||| RB
regarded  ||| S:182 E:191 ||| VBN
as  ||| S:191 E:194 ||| IN
an  ||| S:194 E:197 ||| DT
excellent  ||| S:197 E:207 ||| JJ
source  ||| S:207 E:214 ||| NN
of  ||| S:214 E:217 ||| IN
bioactive  ||| S:217 E:227 ||| JJ
molecules  ||| S:227 E:237 ||| NNS
for  ||| S:237 E:241 ||| IN
human  ||| S:241 E:247 ||| JJ
health ||| S:247 E:253 ||| NN
.  ||| S:253 E:255 ||| .
As  ||| S:255 E:258 ||| IN
part  ||| S:258 E:263 ||| NN
of  ||| S:263 E:266 ||| IN
an  ||| S:266 E:269 ||| DT
on-going  ||| S:269 E:278 ||| JJ
study  ||| S:278 E:284 ||| NN
to  ||| S:284 E:287 ||| TO
elucidate  ||| S:287 E:297 ||| VB
the  ||| S:297 E:301 ||| DT
chemical  ||| S:301 E:310 ||| NN
composition  ||| S:310 E:322 ||| NN
and  ||| S:322 E:326 ||| CC
biological  ||| S:326 E:337 ||| JJ
activity  ||| S:337 E:346 ||| NN
of  ||| S:346 E:349 ||| IN
Marthastherias  ||| S:349 E:364 ||| NNP
glacialis ||| S:364 E:373 ||| NN
,  ||| S:373 E:375 ||| ,
we  ||| S:375 E:378 ||| PRP
report  ||| S:378 E:385 ||| VBP
here  ||| S:385 E:390 ||| RB
the  ||| S:390 E:394 ||| DT
lipidomic  ||| S:394 E:404 ||| JJ
profile  ||| S:404 E:412 ||| NN
of  ||| S:412 E:415 ||| IN
this  ||| S:415 E:420 ||| DT
organism  ||| S:420 E:429 ||| NN
and  ||| S:429 E:433 ||| CC
screening  ||| S:433 E:443 ||| NN
for  ||| S:443 E:447 ||| IN
anticancer  ||| S:447 E:458 ||| JJ
activity ||| S:458 E:466 ||| NN
.  ||| S:466 E:468 ||| .
Two  ||| S:468 E:472 ||| CD
classes  ||| S:472 E:480 ||| NNS
of  ||| S:480 E:483 ||| IN
biologically  ||| S:483 E:496 ||| JJ
active  ||| S:496 E:503 ||| JJ
metabolites  ||| S:503 E:515 ||| NN
were  ||| S:515 E:520 ||| VBD
identified  ||| S:520 E:531 ||| VBN
and  ||| S:531 E:535 ||| CC
quantified  ||| S:535 E:546 ||| VBN
by  ||| S:546 E:549 ||| IN
a  ||| S:549 E:551 ||| DT
GC-MS  ||| S:551 E:557 ||| JJ
optimized  ||| S:557 E:567 ||| JJ
method  ||| S:567 E:574 ||| NN
for  ||| S:574 E:578 ||| IN
screening  ||| S:578 E:588 ||| VBG
several  ||| S:588 E:596 ||| JJ
classes  ||| S:596 E:604 ||| NNS
of  ||| S:604 E:607 ||| IN
metabolites  ||| S:607 E:619 ||| NN
in  ||| S:619 E:622 ||| IN
a  ||| S:622 E:624 ||| DT
single  ||| S:624 E:631 ||| JJ
run ||| S:631 E:634 ||| NN
.  ||| S:634 E:636 ||| .
Free  ||| S:636 E:641 ||| JJ
fatty  ||| S:641 E:647 ||| JJ
acids  ||| S:647 E:653 ||| NNS
and  ||| S:653 E:657 ||| CC
sterols  ||| S:657 E:665 ||| NNS
were  ||| S:665 E:670 ||| VBD
found ||| S:670 E:675 ||| VBN
,  ||| S:675 E:677 ||| ,
including  ||| S:677 E:687 ||| VBG
ergosterol ||| S:687 E:697 ||| NN
,  ||| S:697 E:699 ||| ,
Î²-sitosterol  ||| S:699 E:712 ||| JJ
and  ||| S:712 E:716 ||| CC
cholesterol  ||| S:716 E:728 ||| NN
derivatives ||| S:728 E:739 ||| NNS
,  ||| S:739 E:741 ||| ,
some  ||| S:741 E:746 ||| DT
of  ||| S:746 E:749 ||| IN
which  ||| S:749 E:755 ||| WDT
are  ||| S:755 E:759 ||| VBP
reported  ||| S:759 E:768 ||| VBN
in  ||| S:768 E:771 ||| IN
this  ||| S:771 E:776 ||| DT
species  ||| S:776 E:784 ||| NN
for  ||| S:784 E:788 ||| IN
the  ||| S:788 E:792 ||| DT
first  ||| S:792 E:798 ||| JJ
time ||| S:798 E:802 ||| NN
.  ||| S:802 E:804 ||| .
Distinct  ||| S:804 E:813 ||| JJ
assays  ||| S:813 E:820 ||| NN
were  ||| S:820 E:825 ||| VBD
performed  ||| S:825 E:835 ||| VBN
to  ||| S:835 E:838 ||| TO
screen  ||| S:838 E:845 ||| VB
extract ||| S:845 E:852 ||| NN
's  ||| S:852 E:855 ||| POS
effect  ||| S:855 E:862 ||| NN
on  ||| S:862 E:865 ||| IN
viability ||| S:865 E:874 ||| NN
,  ||| S:874 E:876 ||| ,
membrane  ||| S:876 E:885 ||| JJ
integrity  ||| S:885 E:895 ||| NN
and  ||| S:895 E:899 ||| CC
density  ||| S:899 E:907 ||| NN
of  ||| S:907 E:910 ||| IN
three  ||| S:910 E:916 ||| CD
human  ||| S:916 E:922 ||| JJ
cancer  ||| S:922 E:929 ||| NN
cell  ||| S:929 E:934 ||| NN
lines ||| S:934 E:939 ||| NNS
:  ||| S:939 E:941 ||| :
human  ||| S:941 E:947 ||| JJ
oestrogen  ||| S:947 E:957 ||| JJ
receptor-positive  ||| S:957 E:975 ||| NN
( ||| S:975 E:976 ||| -LRB-
ER ||| S:976 E:978 ||| NNP
( ||| S:978 E:979 ||| -LRB-
+ ||| S:979 E:980 ||| NNP
) ||| S:980 E:981 ||| -RRB-
)  ||| S:981 E:983 ||| -RRB-
breast  ||| S:983 E:990 ||| NN
cancer  ||| S:990 E:997 ||| NN
( ||| S:997 E:998 ||| -LRB-
MCF-7 ||| S:998 E:1003 ||| NNP
) ||| S:1003 E:1004 ||| -RRB-
,  ||| S:1004 E:1006 ||| ,
human  ||| S:1006 E:1012 ||| JJ
neuroblastoma  ||| S:1012 E:1026 ||| NNS
( ||| S:1026 E:1027 ||| -LRB-
SH-SY5Y ||| S:1027 E:1034 ||| NNP
)  ||| S:1034 E:1036 ||| -RRB-
and  ||| S:1036 E:1040 ||| CC
human  ||| S:1040 E:1046 ||| JJ
colon  ||| S:1046 E:1052 ||| NN
cancer  ||| S:1052 E:1059 ||| NN
( ||| S:1059 E:1060 ||| -LRB-
Caco-2 ||| S:1060 E:1066 ||| NNP
) ||| S:1066 E:1067 ||| -RRB-
.  ||| S:1067 E:1069 ||| .
Differential  ||| S:1069 E:1082 ||| JJ
activity  ||| S:1082 E:1091 ||| NN
towards  ||| S:1091 E:1099 ||| IN
the  ||| S:1099 E:1103 ||| DT
three  ||| S:1103 E:1109 ||| CD
cancer  ||| S:1109 E:1116 ||| NN
cell  ||| S:1116 E:1121 ||| NN
lines  ||| S:1121 E:1127 ||| NNS
was  ||| S:1127 E:1131 ||| VBD
found ||| S:1131 E:1136 ||| VBN
,  ||| S:1136 E:1138 ||| ,
SH-SY5Y  ||| S:1138 E:1146 ||| CD
cell  ||| S:1146 E:1151 ||| NN
line  ||| S:1151 E:1156 ||| NN
being  ||| S:1156 E:1162 ||| VBG
the  ||| S:1162 E:1166 ||| DT
most  ||| S:1166 E:1171 ||| RBS
susceptible ||| S:1171 E:1182 ||| JJ
.  ||| S:1182 E:1184 ||| .
No  ||| S:1184 E:1187 ||| DT
activity  ||| S:1187 E:1196 ||| NN
was  ||| S:1196 E:1200 ||| VBD
found  ||| S:1200 E:1206 ||| VBN
for  ||| S:1206 E:1210 ||| IN
Caco-2  ||| S:1210 E:1217 ||| CD
cell  ||| S:1217 E:1222 ||| NN
line ||| S:1222 E:1226 ||| NN
.  ||| S:1226 E:1228 ||| .
Non-cancer  ||| S:1228 E:1239 ||| JJ
cell  ||| S:1239 E:1244 ||| NN
lines  ||| S:1244 E:1250 ||| NNS
( ||| S:1250 E:1251 ||| -LRB-
human  ||| S:1251 E:1257 ||| JJ
dermal  ||| S:1257 E:1264 ||| JJ
fibroblasts  ||| S:1264 E:1276 ||| NN
and  ||| S:1276 E:1280 ||| CC
human  ||| S:1280 E:1286 ||| JJ
foreskin  ||| S:1286 E:1295 ||| JJ
fibroblasts ||| S:1295 E:1306 ||| NN
)  ||| S:1306 E:1308 ||| -RRB-
were  ||| S:1308 E:1313 ||| VBD
also  ||| S:1313 E:1318 ||| RB
tested  ||| S:1318 E:1325 ||| VBN
and  ||| S:1325 E:1329 ||| CC
revealed  ||| S:1329 E:1338 ||| VBD
to  ||| S:1338 E:1341 ||| TO
be  ||| S:1341 E:1344 ||| VB
less  ||| S:1344 E:1349 ||| RBR
susceptible ||| S:1349 E:1360 ||| JJ
.  ||| S:1360 E:1362 ||| .
This  ||| S:1362 E:1367 ||| DT
work  ||| S:1367 E:1372 ||| NN
establishes  ||| S:1372 E:1384 ||| VBZ
M.  ||| S:1384 E:1387 ||| NNP
glacialis  ||| S:1387 E:1397 ||| NN
as  ||| S:1397 E:1400 ||| IN
a  ||| S:1400 E:1402 ||| DT
potential  ||| S:1402 E:1412 ||| JJ
source  ||| S:1412 E:1419 ||| NN
of  ||| S:1419 E:1422 ||| IN
bioactive  ||| S:1422 E:1432 ||| JJ
molecules  ||| S:1432 E:1442 ||| NNS
for  ||| S:1442 E:1446 ||| IN
further  ||| S:1446 E:1454 ||| JJ
studies ||| S:1454 E:1461 ||| NNS
.  ||| S:1461 E:1463 ||| .
